Jin Medical International Ltd. (ZJYL) Stock Price & Analysis
Jin Medical International Ltd. (ZJYL) — MoonshotScore 41/100 (Weak band), calculated Nov 18, 2026. Price $3.34 (-0.60%), as of the Nov 19, 2026 trading session.
Educational signal · not a buy or sell recommendation · How to read this
Jin Medical International Ltd. · ZJYL · NASDAQ
Jin Medical International Ltd. focuses on designing, developing, manufacturing, and selling wheelchairs and other living aids for individuals with disabilities or impaired mobility. The company operates both in China and internationally, offering products like oxygen concentrators and bathing machines.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Jin Medical International (ZJYL)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Strong price action running well ahead of the business — a fragile balance sheet underneath; a move to treat with suspicion, not chase. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Solid; Financial Safety: Fragile; Valuation: Fair; Growth Durability: Fading; Momentum: Rising.
- quarterly revenue $9M (Q2 FY2026, quarter ended Mar 31, 2026)
- Altman Z 2.26 · Piotroski F 3
- ROE 3.9% · ROA 2.1% · current ratio 1.95 · earnings yield 4.3% · free-cash-flow yield -25.4%
Holding back: balance-sheet strain, soft growth
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 42 | Weak | |
| 41 | Weak | |
| 41 | Weak | |
| 41 | Weak | |
| 41 | Weak | |
| 41 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $3.34 |
| Change on the day | -0.60% |
| Price / earnings (trailing) | 23.08 |
| Shares traded on the day | 30.7K |
Price & events
Other perspectives
Council score for Jin Medical International (ZJYL): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 15, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 11, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 11, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Jin Medical International (ZJYL), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Jin Medical International Ltd. (ZJYL) is listed on NASDAQ. It employs 273 people. In Q2 FY2026 it reported revenue of $9M and net income of -$107,735.
What do the latest results show for Jin Medical International (ZJYL)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $9M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $9M | -$107,735 | -$0.01 (diluted) |
| Q4 FY2025 | $11M | $1M | $0.16 (diluted) |
| Q2 FY2025 | $10M | -$89,008 | -$0.01 (diluted) |
| Q4 FY2024 | $13M | $2M | $0.24 (diluted) |
What are the financial strengths and risks for Jin Medical International (ZJYL)?
Short answer · as of
The MoonshotScore pillars rate positive momentum as strengths. What is holding it back is balance-sheet strain, soft growth. The distress and quality screens read Altman Z 2.26 · Piotroski F 3. Trailing ratios: ROE 3.9% · ROA 2.1% · current ratio 1.95 · earnings yield 4.3% · free-cash-flow yield -25.4%.
How does Jin Medical International compare with its peers?
Short answer
Jin Medical International's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $242.61 Nov 18, 2026 | $34.1B | 95 5-pillar Nov 18, 2026 | |
| $420.95 Nov 18, 2026 | $146B | 94 5-pillar Nov 18, 2026 | |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $120.37 Nov 19, 2026 | $5.48B | 83 5-pillar Nov 18, 2026 | |
| $74.52 Nov 19, 2026 | $35.8B | 80 5-pillar Nov 18, 2026 | |
| $140.34 Nov 19, 2026 | $8.90B | 77 5-pillar Nov 18, 2026 | |
| $37.84 Nov 19, 2026 | $49.8B | 72 5-pillar Nov 18, 2026 | |
| $170.29 Nov 19, 2026 | $10.9B | 71 5-pillar Nov 18, 2026 | |
| $15.12 Nov 19, 2026 | $10.3B | 71 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 | |
| $163.40 Nov 19, 2026 | $6.48B | 61 5-pillar Nov 18, 2026 | |
| $25.39 Nov 19, 2026 | $13.1B | 57 5-pillar Nov 18, 2026 | |
| Jin Medical International (ZJYL) — this page | $3.34 | — | 41 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ZJYL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ZJYL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Jin Medical International (ZJYL)?
Jin Medical International Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ZJYL research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ZJYL?
ZJYL carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is ZJYL a good stock to buy?
Stock Expert AI does not rate ZJYL buy, sell or hold. Jin Medical International Ltd. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ZJYL stock price today?
The last price recorded for Jin Medical International Ltd. (ZJYL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ZJYL?
The main risks for Jin Medical International Ltd. include intense competition from larger medical device manufacturers, regulatory changes in the healthcare sector, and economic downturns affecting consumer spending. The company's small market capitalization and high beta also contribute to its risk profile.
What are the key factors to evaluate for ZJYL?
Jin Medical International Ltd. (ZJYL) holds a MoonshotScore in the low range. To weigh it, start with the trailing P/E under Price & valuation on this page. These partnerships can also facilitate access to new customer segments and generate recurring revenue streams. Not financial advice.
How frequently does ZJYL data refresh on this page?
ZJYL's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ZJYL's recent stock price performance?
Jin Medical International Ltd. (ZJYL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized in wheelchair and living aid products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ZJYL overvalued or undervalued right now?
The trailing P/E of Jin Medical International Ltd. (ZJYL) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ZJYL?
Fractional-share availability for Jin Medical International Ltd. (ZJYL) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 12 figures on this page — 9 from Financial Modeling Prep (FMP), 2 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com